Cytokinetics | CYTK - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Arca Biopharma USD 504.48M 15.86M 2026-03
Bayer EUR 107.94B 3.4B 2026-03
Biogen USD 29.48B 43.6M 2026-03
Brainstorm Cell Therapeutics USD 755K 267K 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Capricor Therapeutics USD 326.28M 29.66M 2026-03
Cytokinetics USD 1.27B 151.06M 2026-03
Eisai JPY 1.45T 37.11B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Exelixis USD 2.59B 250.83M 2026-03
Geron USD 534.12M 36.42M 2026-03
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Ligand Pharmaceuticals USD 1.53B 28.53M 2026-03
Merck USD 128.68B 8.18B 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 207.62B 542M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 128.02B 1.22B 2026-03